Osteoporosis Screening: Mixed Messages in Primary Care
Am Fam Physician. 2009 Feb 1;79(3):189-190.
As noted in the article by Sweet and colleagues in this issue of American Family Physician,1 in 2002, the U.S. Preventive Services Task Force (USPSTF) recommended routine screening for osteoporosis in all women 65 years and older and in women 60 to 64 years of age with extra risk factors for osteoporotic fractures.2 These recommendations were assigned a grade B, the same grade given to mammography for breast cancer screening.3 Despite the availability of these evidence-based guidelines, a longitudinal analysis of Medicare claims data showed that only 12.9 percent of female Medicare beneficiaries 65 years and older had diagnostic bone mineral density (BMD) testing in 2005.4 Internists and family physicians had the greatest increases in BMD testing rates (84 and 82 percent, respectively) among all medical specialties submitting Medicare claims between 1999 and 2005, but current rates still fall short of what the USPSTF encouraged.2
The low screening rates are the end product of a puzzling collection of motivating and inhibitory factors in osteoporosis care. Pharmaceutical research has led to the development of safe and cost-effective treatments (especially bisphosphonates),5–7 creating a greater incentive to screen for osteoporosis over the past decade. Clinical performance measures for BMD screening, osteoporosis treatment, and postfracture care8,9 have been planned, but not widely implemented, in the United States. At the same time, drastic legislative cuts in Medicare reimbursement of bone imaging threaten to further decrease the low rates of osteoporosis-related testing. The Centers for Medicare and Medicaid Services has proposed regulations that will cut payments for dual-energy x-ray absorptiometry (DEXA) from $139.46 in 2006 to $55 by 2010,10 which is well below the break-even point of $134 (2007 median total cost per DEXA procedure).11 Because two thirds of DEXA scans are ordered in community offices, patients in rural areas12 and those with low access to hospitals are expected to suffer the most from these changes, when community physicians can no longer support DEXA services in their offices.
These Medicare cuts could prove to be a penny-wise, pound-foolish decision that discourages BMD testing at a time when evidence supports a greater need for it. In particular, one study found that restoring DEXA reimbursement to the 2006 levels could potentially save the Medicare program $1.14 billion over five years because of the reduced number of osteoporotic fractures.13 The U.S. Congress has proposed new bills (Medicare Fracture Prevention and Osteoporosis Testing Act of 2007 [H.R. 4206] and the accompanying Senate bill S.2702) that would freeze DEXA rates at 2006 levels (approximately $140) while a study is conducted on how the cuts will affect patient access to quality osteoporosis testing14; however, the status of these bills is still pending.
How should we approach osteoporosis screening now, considering the mixed messages in primary care? As current financial disincentives make physicians more reluctant to order DEXA scans, it becomes even more important to target screening appropriately. We should encourage screening for all women 65 years and older as recommended by the USPSTF; screening with treatment is highly cost-effective for women in this age range.15 Screening for men has been proposed16,17; however, the cost-effectiveness of this approach depends on treatment costs and other factors,18 and routine screening in men has not been evaluated by the USPSTF. Mass screening in postmenopausal women and men younger than 65 years is not supported by evidence and should be avoided; however, clinical risk factors (low body weight, previous fracture, family history, glucocorticoid use, smoking, alcohol use, and rheumatoid arthritis) can be used to select patients younger than 65 years at higher risk of fracture who could benefit from BMD testing and treatment of osteoporosis.19
The next USPSTF report on osteoporosis screening is being prepared and will reflect further research advances, including findings in men, but important questions about implementation will remain. Hopefully, as new evidence expands our options to prevent and treat osteoporosis in women and men, primary care physicians will be able to implement evidence-based recommendations without financial barriers to appropriate care.
Author disclosure: This work was supported by the National Center for Research Resources grant #K23RR024685. The content of this editorial is solely the responsibility of the author and does not necessarily reflect the official views of the funding agency.
The author thanks Dr. Andrew Laster, Dr. Susan Broy, and Dr. Edward Leib (International Society for Clinical Densitometry) for their comments on an earlier version of this editorial.
Address correspondence to Margaret Gourlay, MD, MPH, at Margaret_gourlay@med.unc.edu. Reprints are not available from the author.
REFERENCESshow all references
1. Sweet MG, Sweet JM, Jeremiah MP, Galazka SS. Diagnosis and treatment of osteoporosis. Am Fam Physician. 2009;79(3):193–200....
2. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Rockville, Md.: Agency for Healthcare Research and Quality; September 2002. http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm. Accessed November 1, 2008.
3. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(5 pt 1):347–360.
4. Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999–2005. J Bone Miner Res. 2008;23(7):1061–1067.
5. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570–578.
6. Kanis JA, Adams J, Borgström F, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008;42(1):4–15.
7. Borgström F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int. 2006;17(7):996–1007.
8. American Medical Association. Consortium performance measures. http://www.ama-assn.org/ama/pub/category/4837.html. Accessed September 23, 2008.
9. National Committee for Quality Assurance (NCQA). HEDIS 2008: Technical Specifications for Physician Measurement. Washington, DC: NCQA; 2008.
10. Binkley N. CMS proposes drastic cuts for DXA and VFA reimbursement. July 21, 2006. International Society for Clinical Densitometry OsteoFlash Newsletter. http://www.iscd.org/Visitors/pdfs/July21OsteoFlash.pdf. Accessed November 1, 2008.
11. The Lewin Group, Inc. Assessing the costs of performing DXA services in the office-based setting. Final report. October 31, 2007. http://www.aace.com/advocacy/leg/pdfs/DXAExecutiveSummary.pdf. Accessed November 1, 2008.
12. Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int. 2003;14(2):146–151.
13. Proposed bill to protect patient access to osteoporosis testing by reversing cuts in Medicare reimbursement. Washington, DC: National Osteoporosis Foundation; November 26, 2007. http://www.nof.org/news/pressreleases/DXA_bill.htm. Accessed November 1, 2008.
14. International Society for Clinical Densitometry. Medicare reimbursement cuts for DXA/VFA. http://www.iscd.org/Visitors/pdfs/ReimbursementFactSheet11-28-07.pdf. Accessed November 1, 2008.
15. Schousboe JT, Ensrud KE, Nyman JA, Melton LJ III, Kane RL. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc. 2005;53(10):1697–1704.
16. Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11(1):75–91.
17. Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians [published correction appears in Ann Intern Med. 2008;148(11):888]. Ann Intern Med. 2008;148(9):680–684.
18. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298(6):629–637.
19. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18(8):1033–1046.
Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Oct 15, 2018
Access the latest issue of American Family Physician